Literature DB >> 3440106

Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite.

N Barzaghi1, G Gatti, F Crema, M Monteleone, C Amione, L Leone, E Perucca.   

Abstract

The serum levels of carbamazepine (CBZ) and its 10,11-epoxide metabolite (CBZ-E) were determined in seven subjects after a single dose of CBZ (400 mg) in the control state and during co-administration of erythromycin (500 mg three times daily for 10 days). Erythromycin treatment was associated with a decrease in CBZ clearance and a prolongation of CBZ half-life, while CBZ-E levels were markedly reduced. These data provide evidence that erythromycin inhibits the conversion of CBZ to its epoxide metabolite.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3440106      PMCID： PMC1386415          DOI： 10.1111/j.1365-2125.1987.tb03257.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  17 in total

1.  Carbamazepine--erythromycin-base interaction.

Authors:  F J Vajda; P F Bladin
Journal:  Med J Aust       Date:  1984-01-21       Impact factor: 7.738

2.  Effect of erythromycin on carbamazepine kinetics.

Authors:  Y Y Wong; T M Ludden; R D Bell
Journal:  Clin Pharmacol Ther       Date:  1983-04       Impact factor: 6.875

3.  Simultaneous liquid-chromatographic determination of carbamazepine and its epoxide metabolite in plasma.

Authors:  R J Sawchuk; L L Cartier
Journal:  Clin Chem       Date:  1982-10       Impact factor: 8.327

4.  Carbamazepine toxicity induced by concurrent erythromycin therapy.

Authors:  E Carranco; J Kareus; S Co; V Peak; S Al-Rajeh
Journal:  Arch Neurol       Date:  1985-02

5.  Carbamazepine-erythromycin interaction. Case studies and clinical significance.

Authors:  B A Wroblewski; W D Singer; J Whyte
Journal:  JAMA       Date:  1986-03-07       Impact factor: 56.272

6.  A case of erythromycin-induced carbamazepine toxicity.

Authors:  W H Berrettini
Journal:  J Clin Psychiatry       Date:  1986-03       Impact factor: 4.384

7.  Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients.

Authors:  E Mesdjian; C Dravet; B Cenraud; J Roger
Journal:  Epilepsia       Date:  1980-10       Impact factor: 5.864

8.  Carbamazepine--erythromycin interaction leading to carbamazepine toxicity in four epileptic children.

Authors:  R Hedrick; F Williams; R Morin; W A Lamb; J C Cate
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

9.  Interaction between carbamazepine and propoxyphene in man.

Authors:  M Dam; C B Kristensen; B S Hansen; J Christiansen
Journal:  Acta Neurol Scand       Date:  1977-12       Impact factor: 3.209

10.  Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction.

Authors:  G J Macphee; G T McInnes; G G Thompson; M J Brodie
Journal:  Lancet       Date:  1986-03-29       Impact factor: 79.321
View more
  4 in total

Review 1.  Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

Authors:  J F Westphal
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

2.  Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications.

Authors:  Carla Carnovale; Marco Pozzi; Faizan Mazhar; Giulia Mosini; Marta Gentili; Gabriëlla G A M Peeters; Emilio Clementi; Sonia Radice
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

Review 3.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 4.  Macrolide antibacterials. Drug interactions of clinical significance.

Authors:  N A von Rosensteil; D Adam
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.